Danielle Curcio

1.4k total citations · 2 hit papers
13 papers, 939 citations indexed

About

Danielle Curcio is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Danielle Curcio has authored 13 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Economics and Econometrics. Recurrent topics in Danielle Curcio's work include Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (4 papers) and Lipid metabolism and disorders (3 papers). Danielle Curcio is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (4 papers) and Lipid metabolism and disorders (3 papers). Danielle Curcio collaborates with scholars based in United States, Australia and Netherlands. Danielle Curcio's co-authors include John J.P. Kastelein, Wolfgang Köenig, Peter Wijngaard, Kausik K. Ray, Frederick J. Raal, David Kallend, Mark Jaros, R. Scott Wright, Lawrence A. Leiter and Traci Turner and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Danielle Curcio

13 papers receiving 907 citations

Hit Papers

Inclisiran for the Treatment of Heterozygous Familial Hyp... 2020 2026 2022 2024 2020 2022 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
    2020 562 citations Frederick J. Raal, David Kallend et al. New England Journal of Medicine profile →
  2. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
    2022 113 citations Stephen J. Nicholls, Marc Ditmarsch et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danielle Curcio United States 6 628 257 204 180 161 13 939
Yassine Zaïr France 20 762 1.2× 487 1.9× 172 0.8× 445 2.5× 62 0.4× 34 1.5k
Cédric Langhi France 15 691 1.1× 156 0.6× 65 0.3× 269 1.5× 90 0.6× 24 1.0k
Douglas Kling United States 13 596 0.9× 368 1.4× 350 1.7× 207 1.1× 61 0.4× 36 1.3k
Hanny Wassef Canada 13 624 1.0× 128 0.5× 70 0.3× 250 1.4× 91 0.6× 17 876
C. Stephen Djedjos United States 13 484 0.8× 398 1.5× 97 0.5× 170 0.9× 161 1.0× 30 1.3k
Gaëlle Asset France 11 408 0.6× 85 0.3× 53 0.3× 197 1.1× 148 0.9× 24 717
Florent Lalanne France 12 545 0.9× 164 0.6× 61 0.3× 287 1.6× 35 0.2× 15 812
Margaret R. Diffenderfer United States 21 923 1.5× 700 2.7× 272 1.3× 257 1.4× 37 0.2× 50 1.4k
Francesca Charlton Australia 10 437 0.7× 203 0.8× 99 0.5× 160 0.9× 47 0.3× 13 766
Martine Paquette Canada 21 721 1.1× 495 1.9× 428 2.1× 191 1.1× 65 0.4× 74 1.2k

Countries citing papers authored by Danielle Curcio

Since Specialization
Citations

This map shows the geographic impact of Danielle Curcio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Curcio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Curcio more than expected).

Fields of papers citing papers by Danielle Curcio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Curcio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Curcio. The network helps show where Danielle Curcio may publish in the future.

Co-authorship network of co-authors of Danielle Curcio

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle Curcio. A scholar is included among the top collaborators of Danielle Curcio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle Curcio. Danielle Curcio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Szarek, Michael, Philip Scheltens, Everard G.B. Vijverberg, et al.. (2025). Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. The Journal of Prevention of Alzheimer s Disease. 13(1). 100394–100394. 1 indexed citations
2.
3.
Nicholls, Stephen J., Adam J. Nelson, John J.P. Kastelein, et al.. (2024). Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials. Pharmacology Research & Perspectives. 12(6). e70010–e70010. 3 indexed citations
4.
Hsieh, Andrew, Michael H. Davidson, Marc Ditmarsch, et al.. (2024). SYNERGISTIC EFFECT OF OBICETRAPIB AND EZETIMIBE ON CIRCULATING LDL PARTICLES. Journal of the American College of Cardiology. 83(13). 1952–1952. 1 indexed citations
5.
Ballantyne, Christie M., Marc Ditmarsch, John J.P. Kastelein, et al.. (2023). Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. Journal of clinical lipidology. 17(4). 491–503. 53 indexed citations
6.
Nicholls, Stephen J., Marc Ditmarsch, John J.P. Kastelein, et al.. (2022). Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nature Medicine. 28(8). 1672–1678. 113 indexed citations breakdown →
7.
Ditmarsch, Marc, Douglas Kling, Danielle Curcio, et al.. (2022). Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial. Journal of clinical lipidology. 16(3). e67–e68. 4 indexed citations
8.
Raal, Frederick J., David Kallend, Kausik K. Ray, et al.. (2020). Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 382(16). 1520–1530. 562 indexed citations breakdown →
9.
Raal, Frederick J., David Kallend, Kausik K. Ray, et al.. (2020). Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia. Atherosclerosis. 315. e7–e8. 1 indexed citations
10.
11.
Offman, Elliot, Sandy Ferber, Judith Johnson, et al.. (2013). Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vascular Health and Risk Management. 9. 563–563. 71 indexed citations
12.
Maki, Kevin C., David G. Orloff, Stephen J. Nicholls, et al.. (2013). A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics. 35(9). 1400–1411.e3. 83 indexed citations
13.
Maki, Kevin C., David G. Orloff, Stephen J. Nicholls, et al.. (2013). A HIGHLY BIOAVAILABLE OMEGA-3 FREE-FATTY ACID REDUCES NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN HIGH-RISK PATIENTS TREATED WITH A STATIN AND RESIDUAL HYPERTRIGLYCERIDEMIA (ESPRIT TRIAL). Journal of the American College of Cardiology. 61(10). E1468–E1468. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yassine Zaïr Breakdown of academic impact, for papers by Cédric Langhi Breakdown of academic impact, for papers by Douglas Kling Breakdown of academic impact, for papers by Hanny Wassef Breakdown of academic impact, for papers by C. Stephen Djedjos Breakdown of academic impact, for papers by Gaëlle Asset Breakdown of academic impact, for papers by Florent Lalanne Breakdown of academic impact, for papers by Margaret R. Diffenderfer Breakdown of academic impact, for papers by Francesca Charlton Breakdown of academic impact, for papers by Martine Paquette
Rankless by CCL
2026